Drug intelligence / Profile preview

LynVir CE

Development stage: Preclinical
Lead developer: Shanghai iCELL Biotechnology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

LynVir CE is an investigational allogeneic virus-specific T-cell (VST) therapy developed by iCELL Biotechnology. It is specifically designed to target and eliminate cells infected with Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV). This cell therapy is intended for the treatment of refractory CMV and EBV infections, which are common and potentially life-threatening complications in immunocompromised patients, such as those undergoing hematopoietic stem cell transplantation (HSCT) or solid organ transplantation. By providing a population of T cells pre-sensitized to viral antigens, LynVir CE aims to restore viral immunity and control infection in cases where standard antiviral pharmacotherapy has failed. The product is currently in the preclinical stage of development.

Brand names: LynVir CE
Other names: LynVir-CEiCELL CMV-EBV VST

Beyond the preview

Go deeper on LynVir CE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LynVir CE.

Explore the full profile